285 related articles for article (PubMed ID: 2995647)
1. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
2. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
3. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
4. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
5. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
7. The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.
Miot F; Erneux C; Wells JN; Dumont JE
Mol Pharmacol; 1984 Mar; 25(2):261-6. PubMed ID: 6321949
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
9. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
11. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
14. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.
Seiler S; Arnold AJ; Grove RI; Fifer CA; Keely SL; Stanton HC
J Pharmacol Exp Ther; 1987 Nov; 243(2):767-74. PubMed ID: 2824759
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
16. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
Vanderwel M; Haslam RJ
J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
[TBL] [Abstract][Full Text] [Related]
17. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Cook NS; Bruttger O; Pally C; Hagenbach A
Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of a potent, new antithrombotic agent, 6-methyl-1,2,3,5-tetrahydroimidazo[2, 1-b] quinazolin-2-one hydrochloride monohydrate.
Fleming JS; Buyniski JP; Cavanagh RL; Bierwagen ME
J Pharmacol Exp Ther; 1975 Aug; 194(2):435-49. PubMed ID: 1151769
[TBL] [Abstract][Full Text] [Related]
19. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
20. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
